Cullinan Therapeutics, Inc.

CGEM Nasdaq CIK: 0001789972

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address ONE MAIN STREET, CAMBRIDGE, MA, 02142
Mailing Address ONE MAIN STREET, CAMBRIDGE, MA, 02142
Phone 617-410-4650
Fiscal Year End 1231
EIN 813879991

Financial Overview

FY2025

$39.64M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
10-K Annual financial report March 10, 2026 View on SEC
4 Insider stock transaction report March 9, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 4, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 25, 2026 View on SEC
4 Insider stock transaction report February 25, 2026 View on SEC
4 Insider stock transaction report February 25, 2026 View on SEC
4 Insider stock transaction report February 25, 2026 View on SEC

Annual Reports

10-K March 10, 2026
  • CLN-049 (BTK Degrader) successfully completed Phase 2 dose-escalation with promising safety and preliminary efficacy signals, initiating a Phase 2 expansion cohort.
  • CLN-418 (TL1A Antibody) received IND clearance and began Phase 1 clinical trial, expanding the immunology pipeline.
View Analysis

Insider Trading

STRONG SELL 5 insiders 22 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.